<DOC>
	<DOCNO>NCT02723877</DOCNO>
	<brief_summary>This study open-label , non randomize , multi-center , phase 1/2b ( dose escalation follow expansion part ) study evaluate clinical safety , efficacy pharmacokinetics PQR309 combination standard dose eribulin patient locally advanced metastatic HER2-negative ( escalation part ) Triple Negative Breast Cancer ( expansion part ) .</brief_summary>
	<brief_title>PQR309 Eribulin Metastatic HER2 Negative Triple-negative Breast Cancer ( PIQHASSO )</brief_title>
	<detailed_description>- The primary objective escalation part ass maximum tolerate dose ( MTD ) PQR309 combine standard eribulin dose patient HER2 negative breast cancer follow `` modify '' 3 3 design . - For expansion part objective evaluate efficacy PQR309 combination eribulin patient Triple Negative Breast Cancer - Once MTD continuous daily PQR309 dosing establish , intermittent schedule PQR309 ( `` 2 day on/ 5 day '' `` Monday / Thursday '' ) evaluate .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>Histologically/cytologically confirm diagnosis breast cancer . Radiological evidence inoperable locally advanced metastatic breast cancer . HER2 negative breast cancer ( base recent analyzed biopsy ) define negative situ hybridization test immunohistochemistry status 0 , 1+ 2+ . Received least 2 5 prio chemotherapeutic regimen locally advance and/or metastatic setting . Prior therapy include anthracycline taxane combination order . For Expansion part : Triplenegative breast cancer define negative situ hybridization test immunohistochemistry ( IHC ) status 0,1+ 2+ER abnd PR status &lt; 10 % local laboratory test . Previous systemic treatment PI3K , mTOR AKT inhibitor ( allow escalation part ) . Previous treatment eribulin ( allow escalation part ) . Known hypersensitivity excipients PQR309 eribulin.Concurrent treatment approve investigational antineoplastic agent . Symptomatic Central Nervous System metastases . The patient must complete prior local treatment CNS metastases &gt; 28 day prior first dose study drug ( include radiotherapy and/or surgery ) . Clinically manifest diabetes mellitus ( treat and/or clinical sign fast glucose &gt; 125mg/dl HbA1c &gt; 7 % ) , document steroid induce diabetes mellitus .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>